secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001193125-26-018700
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences appoints Laurie Stelzer as independent director and audit committee chair
--------------------------------------------------------------------------------

- Laurie Stelzer appointed as Class I director effective Jan. 20, 2026, filling an existing board vacancy.
- Stelzer will serve as chair of the Audit Committee, replacing Ed Mathers on that committee.
- She brings CFO experience from Kailera, Orna, Mirati, Arena, Halozyme, and board roles at Sionna, PMV, Spyre.
- Board size increased to eight directors; Stelzer is independent under Nasdaq standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526018700/0001193125-26-018700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526018700/mbx-20260120.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-018700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer